PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 6530595

Protocol for efficient plasma sampling for low density lipoprotein turnover studies.

N A Le·H N Ginsberg·W V Brown
View original source ↗Export metadata ↓

Abstract

Radiolabeled low density lipoprotein (LDL) is commonly used to study the turnover of LDL apolipoprotein B (apoB), the major protein component of LDL. Following an intravenous injection of radioiodinated LDL, typical sampling schedules have including 20-25 samples over a 14-day period with frequent sampling during the first 12 hr and daily samples thereafter. This is a burdensome task for subjects and investigators. To improve acceptance of the procedure, we have examined the effects of reduced sampling schedules upon the estimation of the fractional catabolic rate (FCR) for LDL apoB. Data from 36 different sets of LDL decay curves obtained from investigations of subjects with a variety of lipoprotein phenotypes have been used to test these schedules. Our results indicate that by choosing specific intervals over a 14-day period only 10 samples are sufficient to accurately determine the fractional catabolic rate for LDL in plasma. This reduced sampling schedule should facilitate the study of LDL turnover in large groups of subjects as outpatients.

Explore related subjects

Apolipoproteins BHumansKineticsLipoproteins, LDLJournal ArticleResearch Support, Non-U.S. Gov'tResearch Support, U.S. Gov't, P.H.S.

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

N A Le, H N Ginsberg, W V Brown. 1984-12-01. Protocol for efficient plasma sampling for low density lipoprotein turnover studies.. https://pubmed.ncbi.nlm.nih.gov/6530595/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1995

Inhibition of metal-catalyzed oxidation of low-density lipoprotein by free and albumin-bound bilirubin.

Both free and albumin-bound bilirubin are known to scavenge peroxyl radicals in vitro. In the present work we showed that free and albumin-bound bilirubin at the physiological concentration of the bile pigment in blood plasma could greatly inhibit the metal-catalyzed oxidation of low density lipoprotein (LDL) as shown by the reduced thiobarbituric acid reactivity, smaller or no shifts in electrophoretic mobility, less apo B fragmentation and a decreased amount of cholesterol oxidation products as detected by gas chromatography. Free bilirubin (BR) was more effective in inhibiting the production of thiobarbituric acid reactive substances in iron-catalyzed LDL peroxidation as compared to the copper-catalyzed reaction up to a BR to metal molar ratio of 4:1. Above this ratio the same degree of inhibition was observed for both metal ions. It was found that serum albumin provided full protection against Cu(2+)-dependent oxidative stress only at very high protein to metal molar ratio, i.e., 30:1, that is similar to that in human plasma. Complexation of BR to albumin brought about a marked increase in the capacity of the complex to bind metal ions, particularly iron, as opposed to albumin alone. At a molar ratio of metal ion to albumin-BR of 1:1 the inhibition of lipid peroxidation was about 96% and it was almost complete at a molar ratio of 1:2. The ability of albumin-BR complex to inhibit effectively the transition metals-dependent oxidative stress could be important in the extravascular space where local concentrations of metal ions may exceed the protein binding capacity. In addition, the strong binding of iron to the albumin-BR complex may be clinically important, especially in iron loaded sera of hemochromatosis patients, where the transferrin is fully saturated with this ion and the free iron could catalyze lipid peroxidation unless bound by a metal trapping device such as the albumin-BR complex.

Apolipoproteins B↗
PubMed1995

Identification and molecular analysis of two apoB gene mutations causing low plasma cholesterol levels.

BACKGROUND: Familial hypobetalipoproteinemia (FHB) is an autosomal codominant disorder characterized by abnormally low plasma levels of apoB and LDL cholesterol. Heterozygotes for FHB almost always have plasma LDL cholesterol levels < 70 mg/dL and are asymptomatic. Because the low cholesterol levels may protect FHB heterozygotes from coronary heart disease, the mechanisms for FHB are of considerable interest. METHODS AND RESULTS: The plasma lipoproteins of 29 subjects with LDL cholesterol levels < 70 mg/dL were examined by SDS-PAGE. One subject who had virtually undetectable levels of LDL cholesterol had a truncated apoB, apoB-44.4, in his lipoproteins; a second subject with an LDL cholesterol level of 44 mg/dL had apoB-55 in his lipoproteins. The apoB-44.4 (2014 amino acids in length) resulted from a frameshift caused by an 11-bp insertion in exon 26 of the apoB gene; the apoB-55 (2494 amino acids) was caused by a nonsense mutation in exon 26 of the apoB gene. The apoB-55 mutation occurred at a CpG dinucleotide pair, a mutational hot spot, and was identical to a mutation described previously in a subject with hypobetalipoproteinemia. Our subject with apoB-55, however, had a different haplotype than the subject described previously, suggesting that the two apoB-55 mutations may have arisen independently. Of note, the apoB-55 proband's father, who had very low cholesterol levels and who probably carried the apoB-55 mutation, had significant coronary and aortic atherosclerosis at autopsy. CONCLUSIONS: In a study of adults with low LDL cholesterol levels, we discovered two subjects with truncated apoB proteins and identified the responsible mutations. ApoB gene mutations causing truncated apoB are not particularly rare in subjects with low cholesterol levels. The role of these mutations in preventing atherosclerosis deserves further study.

Apolipoproteins B↗
PubMed1995

Comparison of effects of N-3 to N-6 fatty acids on serum level of lipoprotein(a) in patients with coronary artery disease.

The influence of dietary supplementation with n-3 versus n-6 fatty acids on plasma lipoprotein(a) (Lp[a]) levels was studied. Thirty-five male hospitalized patients with coronary artery disease were treated for 4 weeks with 12 g/day of fish oil (approximately 8.5 g of n-3 fatty acids) in combination with a 5,000 kilojoule, 30% fat diet and moderate exercise. Eighteen control patients given the same dietary and training program were treated with 12 g/day of rapeseed oil. Plasma Lp(a), in addition to several lipids and lipoproteins, blood clotting factors, and platelet reactivity, were measured before and at the end of therapy. Results can be summarized as follows: total cholesterol, low-density lipoprotein cholesterol, and apolipoprotein B levels decreased significantly in both the rapeseed oil (-14.4%, -20.3%, -15.2%, respectively) and fish oil (-12.2%, -16.0%, and -14.2%, respectively) groups. Triglycerides decreased (-20.3%) and high-density lipoprotein cholesterol increased (+8.3%) significantly only in patients treated with fish oil. Plasma Lp(a) levels were reduced by 14% in the fish oil group, but unaffected in the rapeseed oil group. Patients treated with fish oil could be categorized into 2 subgroups: "responders," with a reduction in Lp(a) by 24% and "nonresponders," with a small nonsignificant increase in serum Lp(a). Responders and nonresponders exhibited a marked reduction in cholesterol, low-density lipoprotein cholesterol, apolipoprotein B, and triglycerides, and an increase in high-density lipoprotein3 cholesterol. There was a large reduction in tissue plasminogen activator in the fish oil group, which correlated significantly with reduction in Lp(a).(ABSTRACT TRUNCATED AT 250 WORDS)

Apolipoproteins B↗